Post on 03-Oct-2020
Development o f No vet Fomndatians.... References
176
Aggarwal, B. B. (2,008). "Prostate cancer and curcumin: add spice to your life." Cancer
Biol Ther 7(9): 14364 440,
Ahmad, Z., R. Pandey, et al. (2006). "Pharmacokinetic and pharmacodynamic
behaviour of antituberciilar drugs encapsulated in alginate nanoparticles at two
doses," Intenuitional Journal of Antimicrobial Agents 27(5): 409-416.
Alt, S., A. Ahmad, et al. (2010). "Gemcitabine sensitivity can be induced in pancreatic
cancer cells tlirough modulation of rniR-200 and miR-2f expression by
curcumin or its analogue CDF." Cancer Res 70(9): 3606-3617.
Allemann, E., R. Gurny, et al. (1992). "Preparation of aqueous polymeric
nanodispersions by a reversible salting-out process: influence of process
parameters on particle size." Int. J. Pharm. 87(1-3): 247-253.
Anarid, P., A. B, Kunnumakkara, et al. (2007). "Bioavailability of curcumin; problems
and promises." Mol Pharm 4(6); 807-818.
Anand, P., H. B. Nair, et al. (2010). "Design of curcumin-loaded PLGA nanoparticles
formulation with enhanced cellular uptake, and increased bioactivity in vitro
and superior bioavaiiability in vivo." Biochem Phannacol 79(3): 330-338.
Anand, P., C. Sundaram, et al. (2008). "Curcumin and cancer: an "old-age" disease w ith
an "age-old" solution." Cancer Lett 267(1); 133-164.
Ansari, M. .T„ S. Ahmad, et al. (2005). "Stability-indicating HPTLC determination of
curcumin in bulk drug and pharmaceutical formulations." J Pharm Biomed Anal 39(1-2): 132-138.
Anuchapreeda, S., P. Limtrakiil, et ai. (2006). "Inhibitory effect of curcumin on WTl
gene expression in patieiV leukemic cells." Arch Pharm Res 29(1); 80-87.
Arbos, P., M. A. Campanero, et al. (2004). "Nanopaiticles with specific bioadhesive
properties to circumvent the pre-systemic degradation of fluorinated
pyrimidines." J. Control. Release 96(1): 55-65.
Arun, N. and N. Nalini (2002). "Efficacy of turmeric on blood sugar and polyol
pathway in diabetic albino rats." Plant Foods Hum Nutr 57(1): 41-52.
Atsumi, T., S. Fujisawa, et al. (2005). "Relationship between intracellular ROS
production and membrane mobility in curcumin- and tetrahydrocurcumin-
treated human gingival fibroblasts and human submandibular gland carcinoma
cells." Oral Pis 11(4): 236-242.
Development o f Novel Formulations.. ..References
l l i lR e fe re n e e s
..~ T t7" ~
Development o f Novel Fonnulaiions.... References
At.sumi, T., K. Tonosaki, et al. (2006). "Induction of early apoptosis and ROS-generation activity in human gingival fibroblasts (HGF) and human
submandibular gland carcinoma (HSG) cells treated with curcuniin." Arch Oral
Biol 51(10): 913-921.
Attwood, D. and A. T. Florence (1983). Surfactant systems: tlieir chemistry, pharmacy
and biolQ?j:v. London, Chapman and Hall.
Balachandran, P. and R. Govindarajan (2005). "Cancer-an ayurvedic perspective."
PlKirmacol Res 5 J (1): 19-30.
Balakrishnan, P., B. J. Lee, ct al. (2009). "Enhanced oral bioavailability of Coenzyme
QIO by seif-emulsifying datg delivery systems." International journal of
pharmaceutics 374( 1 -2): 66-72.
Barichello, J. M., M. Morishita, et al. (1999). "Absorption of insulin from Pluronic F-
127 gels following subcutaneous administration in rats." Int. J. Pharm. 184(2);
189498.
Bava, S. V., V. T. Puliappadamba, et ai. (2005). "Sensitization of taxoHnduced
apoptosis by curcumin involves dov\/n-regulation of nuclear factor-kappaB and
the serine/threonine kinase Akt and is independent of tubulin polymerization." J
Biol Chem 280(8): 6301^6308.
Bhakuni, D. S., M. L. Dhar, et al. (1969). "Screening of Indian plants for biological
activity. II." Indian J Ext) Biol 7(4): 250-262.
Bisht, S., G. Feldmann, et ai. (2007). "Polymeric nanoparticle-encapsulated curcumin
("nanocurcumin"): a novel strategy for human cancer therapy." J
Nanobiotechnology 5: 3.
Borhade, V., H. Nair, et al. (2008). "Design and evaluation of self-microemulsifying
drug delivery system (SMEDDS) of tacrotimus." AAPS PharmSciTcch 9(1):
13-21.
Cai, X. Z., J. Wang, et al. (2009). "Curcumin suppresses proliferation and invasion in
human gastric cancer cells by downregulation of PAKl activity and cyclin D1
expression." Cancer Biol Ther 8(14): 1360-1368.
Camacho-Barquero, L., I. Villegas, et al. (2007). "Curcumin, a Curcuma longa
constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS
expression in chronic experimental colitis." Int Immunopharmacol 7(3): 333-
342.
178
DevcUipweit! o f Novel Formulations....References
c,’ao, F. L,., Y. W. Xi, et al. (2009). "fPrepai'atiori and characterization of curcumin
loaded gelatin microspheres for lung targeting]." Zhong Yao Cat 32(3); 423-
426.
Carino, G. P., J. S. Jacob, et al. (2000). "Nanosphere based oral insulin delivery," J.,
Control. Release 65(1-2): 261-269.
Ciien, C., X. Huang, et a!. (2010). "Anti-prolifcration and anti-angiogene-sis of
curcumin-K30 solid dispersion." Zhong Nan Da Xue Xiie Bao Yi Xue fiati
35(10): 1029.1036.
Chen, M. L, (2008), "Lipid excipients and delivery systems for pharmaceutical
development: a regulatory perspective." Adv Drug Deliv Rev 60(6): 768-777.
Cheng, A. L., C. H. Hsu, et al. (2001). "Phase I clinical trial of curcumin, a
chemopreventive agent, in patient,s with high-risk or pre-malignant lesions."
Anticancer Res 21(4B): 2895-2900.
Chin, S. F,, K. S. Iyer, et al. (2009). "Encapsulation and sustained release of curcumin
using superparamagnetic silica reservoirs." Chemistry 15(23): 5661-5665.
Choudhuri, T., S. Pal, et al. (2002). "Curcumin induces apoptosis in human breast
cancer cells through p53-dependent Bax induction." FEBS Lett 512(1-3): 334-
340.
ChromaDex (2003). Determination of Curcuminoids in Turmeric Extract by HPLC.
Churchill, M., A. Chadbum, et al. (2000). "Inhibition of intestinal tumors by curcumin
is associated with changes in the intestinal immune cell profile." J Sure Res
89(2): 169-175.
Constantinides, P. P. (1995). "Lipid microemulsions for improving dmg dissolution and
oral absorption: physical and biopharmaceutical aspects." Pharm Res 12(11):1561‘-1572.
Corporation, P. (2007). WinNonlin User's Guide Verion 5.2, Pharsight Corporation,
321 E. Evelyn Ave., 3rd Floor, Mountain View, California
Corsi, M. M., A. A. Bertelli, et al (1998). "The therapeutic potential of Aloe Vera in
tumor-bearing rats." Int J Tissue React 20(4): 115-118.
Craig, D. Q., S, A. Barker, et al. (1995). "An investigation into the mechanism of self
eraulsification using particle size analysis and low frequency dielectric
spectroscopy." International Journal of Pharmaceutics 114; 103-110.
Craig, D. Q., H. S. R, Lievens, et al. (1993). "An investigation into the physicochemical
properties of self emulsifying systems using low frequency dielectric
i w ....
Development o f Novel Fonnulations..,. References
spectroscopy, surface tension measurements and particle size analysis.
Internationai Journat of Pharmaceutics 96( I -3): i 47-155.
Ciii, J-, B. Yu, et al. (2009). "Enhancement of oral absorption of curcumin by self-
microemulsifying drug delivery systems." Int J Pharm 371(1-2): 148-155,
Cui, S. X., S. F. Nie, et al. (2009). "Preparation and evaluation of self-ralcroemulsifying
drug delivery system containing vinpocetine." Drug Dev Ind Pharm 35(5): 603-
611.
D'Ambrosio, S. M., R. Gibson-D'Ambrosio, et al. (2000). "Differential response of
normal, prenialignant and malignant human oral epithelial cells to growth
inhibition by chemopreventive agents." Anticancer Res 20(4): 2273-2280.Dai, J,, T. Nagai, et al. (2004). "pH-sensitive nanoparticles for improving the oral
bioavailability of cyclosporine A." Int. J. Pharm. 280(1-2): 229-240.
Damge, C., C. Michel, et ai. (1988). "New approach for oral administration of insulin
with polyalkylcyanoacrylate nanocapsules as drag carriers." Diabetes 37: 37.
Dance-Barnes, S. T., N. D. Kock, et al. (2009). "Lung tumor promotion by curcumin."
Carcinogenesis 30(6): 1016-1023.
Dandekar, P., R, Dhumal, et ai. (2010). "Toxicologicai evaluation of pH-sensitive
nanoparticles of curcumin: acute, sub-acute and genotoxicity studies." Food
Chan Toxicol 48(8-9): 2073-2089.
Dandekar, P. P., R. Jain, et al. (2010). "Curcumin-loaded hydrogel nanopaiticles:
application in anti-malarial therapy and toxicologicai evaluation." J Pharm Sol
99(12): 4992-5010.
Das, R. K., N. Kasoju, et al. (2010). "Encapsulation of curcumin in algiiiate-chitosan-
pluronic composite nanoparticles for delivery to cancer cells." Nanomedicine
6(1): 153-160.
Deeb, D., H. Jiang, et al. (2004). "Curcumin sensitizes prostate cancer cells to tumor
necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear
factor-kappaB through suppression of IkappaBalpha phosphorylation." Mol
CancerTher3(7): 803-812.
Deodhar, S. D., R. Sethi, et al. (1980). "Preliminary study on antirheumatic activity of
curcumin (diferuloyl methane)." Indian J Med Res 71: 632-634.
Devani, M., M. Ashford, et al. (2004). "The emulsification and solubilisation properties
of polyglycolysed oils in self-emulsifying formulations." J Pharm Pharmacol
56(3): 307-316.
~ i w ......
Development o f Novel Formukitions....References
Devasena, T-, K. N. Rajasekaran, et ai. (2003). "Anticarcinogenic effect of bis-l,7-(2-
hydroxyphenyl)-hepta-l,6-diene-3,5-dione a ciircumin analog on DMH-induced
coion cancer model." Pliarmaco! Re.s 47(2): 133-140.
f3har, M. L., M. M, Dhar, et al. (1968). "Screening of Indian plants for biological
activity: I." Indian J Exp Biol 6(4): 232-247.
Dhawan, B. N., M. P. Dubey, et ai. (1980). "Screening of Indian plants for biological
activity: Part IX." Indian Exp Biol 18(6): 594-606.
Di Mario, F., N. Stefani, et al. (2006). "A new curcumin-ba.sed one week therapy for
eradication of H. pylori infection." Dige.stive and Liver Disease 38(Supplement
l);S71"S71.
Divya, C. S. and M. R. Pillai (2006). "Antitumor action of curcumin in human
papillomavirus associated cells involves downregulation of viral oncogenes,
prevention of NFkB and AP-1 tran.slocation, and modulation of apoptosis," Mol
Carcinoe 45(5): 320-332.
Duan, J,, Y. Zhang, et al. (2010). "Synthesi,s and in vitro/in vivo anti-cancer evaluation
of curctimin-loaded chitosan/poIy(butyf cyanoacrylate) nanoparticles." fnt J
Phaaa 400(1-2): 211-220.
Eigner, D. and D. Scholz (1999). "Ferula asa-foetida and Curcuma longa in traditional
medical treatment and diet in Nepal." J Ethnopharmacol 67(1): 1-6.
El-Shabouri, M. H. (2002). "Positively charged nanoparticles for Improving the oral
bioavailability of cyclosporin-A." Int. J. Pharm. 249(1-2): 101-108.
Elattar, T. M. and A. S. Virji (2000). "The inhibitory effect of curcumin, genistein,
quercetin and cisplatin on the growth of oral cancer cells in vitro." Anticancer
Res 20(3A): 1733-1738.
FDA, U. (2010, 10/08/2010). "Generally Recognized as Safe (GRAvS)." 2010, from
http://www.fda.gov/Food/FoodIngredientsPackaging/GenerallvRecognizedasSa
feGRAS/defauit.htm.
FDA, U. (2010). "Inactive Ingredient Search for Approved Drug Products." 2010, from
http://www.acce.ssdata.fda.gov/scriDts/cder/iig/index.cfm.
Frank, N„ J. Knauft, et al. (2003). "No prevendon of liver and kidney tumors in Long-
Evans Cinnamon rats by dietary curcumin, but inhibition at other sites and of
metastases." Mutat Res 523-524: 127-135.
181
Developnwnl o f Novel Formulations. ...References
Frautsch}^ S. A., W. Hu, et al. (2001). "Phenolic anti-inflammatory antioxidant reversai
of Abeta-induced cognitive deficits and neuropathology." Neurobiol Aging
22(6): 993-1005.
Gaedeke, J., N. A. Noble, et al. (2004). "Cufcumin blocks rnuitiple sites of the TGF"
beta signaling cascade in renal ceJis." Kidney Int 66(1); 112-120.
Ganta, S. and M. Amiji (2009). "Coadministration of Paclitaxel and curcumin in
nanoemuision formulations to overcome multidrug resistance in tumor cell,s."
Mol Pharm 6(3): 928-939.
Gao, P., B. D. Rush, et al. (2003). "Development of a supersaturable SEDDS (S-
SIEDDS) formulation of paclitaxel with improved oral bioavailability." J Pharm
,Sd92(!2):2386..2398.Gao, Y., Z. Li, et al. (2010). "Preparation and characterization of intravenously
injectable curcumin nanosuspension." Daig Deliv.
Garcea, G., D. P. Berry, et al (2005). "Consumption of the putative chemopreventive
agent curcumin by cancer patients; assessment of curcumin levels in the
colorectum and their pharmacodynamic consequences." Cancer Epidemiol
Biomarkers Prev 14(1): 120-125.
(jershanik, T. and S. Benita (1996). "Positively charged self-emulsifying oil
formulation for improving the oral bioavailability of progestrone." Pharm Dev
Technol 1; 147--157.
Gershaniic, T. and S. Benita (2000). "Self-dispersing lipid formulations for improving
oral ab.sorption of lipophilUc drugs." Eur J Pharm Biopharm 50(1): 179-188.
Ghosh, M., A. T. Singh, et al. (2010). "Curcumin nanodisks: formulation and
characterization." Nanomedicine.
Giladi, N.,‘D. Kazanov, et al. (2010). "Curcumin potentiates the pro-'apoptotic effects of
sulindac sulfone in colorectal cancer." Expert Qpin Inve.stig Drugs 19 Suppl I:
Si 17-124.
Godddeeris, €., F. Cuppo, et a l (2006). "Light scattering measurements on
microemulsion: Estimation of droplet sizes." International Journal of
Pharmaceutics 3t2ri-2): 187-195.
Goel, A., A. B. Kummmakkara, et al. (2008). "Curcumin as "Curecumin": from kitchen
to clinic." Biochem Pharmacol 75(4): 787-809.
Goodman, L., A. Gilman, et al. (2006). Goodman and Gilman's the pharmacological
basis of therapeutics. McGravt'-Hill.
...
Devclopmeni o f Novel Formulatiom... .References
Govender, T.,, S. Stolnik, et, al. (1999). "PLGA nanoparticles prepared by
nanoprecipitaticm: drug loading and release studies of a water soluble drug." L
Control. Release 57(2); 171-185.
Guiu'rero, Q., E. AiJemann, et ai. (1998). "Preparation techniques and mechanisms of
fonTiation of biodegradable naaopardcles from preformed polymers." Drug Dev.
fnd. Pharm. 24: 1113-1128.
Gukovsky, f., Cl N. Reyes, et al. (2003). "Curcumin ameliorates ethanol and nonethanol
experimental pancreatitis." Am J Phvsiol Gastrointest Liver Physiol 284(1):
G85-9.5.
Guo, F. and C. J. Xu (2005). "[Progress on the study of mechanism of the direct action
of TCM bioactive components on ovarian cancer]." Zhongguo Zhone Xi Yi .fie
He Za Zhi 25( 12): 1! 40-1144.
Gupta, V., A. A.seh, et al. (2009). "Fabrication and characterization of silk fibroin-
derived curcumin nanoparticles for cancer therapy." Int .T Nanomedicine 4: 115-
122.
Gursoy, N., J. S. Garrigue, et a l (2003). "Excipient effects on in vitro cytotoxicity of a
novel paclitaxel .self-emulsifying drug delivery system." ,f Pharm Sci 92(12):
2411-2418.
Gururajan, M., T. Dasu, et ai. (2007). "Spleen tyrosine kinase (Syk), a novel target of
curcumin, is required for B lymphoma growth." J Immunol 178(1): 111-121.
Han, S. S., Y. S. Keum, et a l (2002). "Curcumin suppresses activation of NF-kappaB
and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia
cells." J Biochem Mol Biol 35(3): 337-342.
Hans, M. L. and A. M. Lowman (2002). "Biodegradable nanoparticles for drug delivery
and targeting." Curr. Qpin. Solid State and Mater. Sci. 6: 319-327.
Harada, K., T. Okiyoneda, ct al. (2007). "Curcumin enhances cystic fibrosis
transmembrane regulator expression by down-regulating caireticulin." Biochem
Biophvs Res Commun 353(2): 351-356.
Hauss, D. J., S. E. Fogal, et al. (1998). "Lipid-based delivery systems for improving the
bioavaiiability and lymphatic transport of a poorly water-soluble LTB4
inhibitor." J Pharm Sci 87(2): 164-169.
Hecq, J., M. Deleers, et al. (2006). "Preparation and in vitro/in vivo evaluation of nano
sized crystals for dissolution rate enhancement of ucb-35440-3, a highly dosed
183
Development o f Novel I'ormulatkms....References
poorly water-soluble weak base." European Journai of Pharmaceutics and
Biopharniaceiitlcs 64(3); 360-368.
Hilchie, A. L., S. J. Fiuiong, et al. (2010), "Curciirain-induced apoptosis in PC3
prostate carcinoma cells is caspase-independt^nt and involves cellular ceramide
accumulation and damage to mitochondria." Nutr Cancer 62(3): 379-389.
Holt, P. R., S. Katz, et al, (2005). "Curcumiti therapy in. inflammatory bow'd disea.se: a
pi lot study." Dig Di.s Scl 50( 11): 2191 ~2193.
Hostanfika., K., G. Daum, et al. (2002),, "Cytostatic and apoptosis-iriducing activity of
boswellic acids toward malignant cell lines in vitro." Anticancer Res 22(5):
2853^2862.
Hour, T. C., J. Chen, ct ai. (2002). "Cisrcumin enhances cytotoxicity of
chemotherapeutic agents in prostate cancer cells by inducing p21(WAFl/CIPi)
and C/EBPbeta expressions and suppressing NF-kappaB activation." Prostate
51(3): 211-218.
Hu, X., B. N. Cao, et ai. (2002). "Attenuation of cell migration and induction of ceil
death by aged garlic extract in rat sarcoma cells." Int J Mol Med 9(6): 641-643.
Hoang, A. C., S. Y, Lin, et al. (2008). "Effects of curcumin on N-bis(2-hydroxypropyl)
nitrosamine (DHPN)-induced lung and liver tumorigenesis in BALB/c mice in
vivo." In Vivo 22(6): 781-785.
Ichiki, K., N, Mitani, et al. (2000). "Regulation of activator protein-1 activity in the
mediastinal lymph node metastasis of lung cancer." Clin Exp Metastasis 18(7):
539-545.
Ireson, C„ S, Orr, et al. (2001). "Characterization of metabolite. of the
chemopreventive agent curcumin in human and rat hepatocytes and in the rat in
vivo, and evaluation of their ability to inhibit phorbol ester-induced
prostaglandin E2 production." Cancer Res 61(3): 1058-1064.
Ireson, C, R., D. J. Jones, et al. (2002). "Metabolism of the cancer chemopreventive
agent curcumin in human and rat intestine." Cancer Epidemiol Blomarkers Prev
11(1): 105-111.
Itokawa, H., K. Takeya, et al. (1984), "Cell grovi/th-inhibitory effects of derivatives of
antituraor cyclic hexapeptide RA-V obtained from Rubiae radix (V)." Gann
75(10): 929-936.
184
D evelopm ent o f N ovel F o n u u ia tio n s. ...R tfe re n c ex
Jiiiswal. S. Kumar Gupta, et a l (2004). "Preparation of biodegradable cyclosporine
nanoparticles by high-pressure emulsification-solvent evaporation process." L
Control Release 96(!): 169-178.
Johnson, C. B. and A. N. Mattia. (2010). "840. Curcumin (WHO Food Additives Series
35)." 2010, from
http://www.inchem.Org/document.s/iecfa/iecmono/v35ie09.htm.
Johnson, S. M., P. Gulhati, et al. (2009). "Curcumin inhibits proliferation of colorectal
carcinoma by modulating Akt/mTOR signaling." Anticancer Res 29(8); 3185-
3190,
Jung, S., N. <3tberg, et al. (2006). "Innovative liposomes as a transfbllicular drug
delivery system: penetration into porcine hair follicles." .T Invest Dermatol
126(8); 1728-1732.
Kakkar, Y,, S. Singh, et al. (2010). "Exploring solid lipid nanoparticles to enhance the
oral bioavailiibility of curcumin." Mol Ntitr Food Res.
Kang, B. K., J. S. Lee, et al. (2004). "Development of seif-microemulsifying drug
delivery systems (SMEDDS) for oral bioavailability enhancement of
simvastatin in beagle dogs," Int J Pharm 274(1-2): 65-73.
Kelloff, G,, J. Crowell, et al (1996). "Clinical development plan: curcumin." J Cell
Biochem Suppl 26: 72-85.
Kempaiah, R. K. and K. Srinivasan (2002). "Integrity of erythrocytes of
hypercholesteroiemic rats during spices treatment," Mol Cell Biochem 236(1-
2): 155-161.
Khoo, S. M., A. J. Humberstone, et al. (1998). "Formulation design and bioavailabiiity
assessment of lipidic self-emulsifying formulations of halofantrine."
International Journal of Pharmaceutics 167(1-2): 155-164, ’
Kim, .1. Y. and Y. S. Ku (2000). "Enhanced absorption of indomethacin after oral or
rectal administration of a self-emulsifying system containing indomethacin to
rats." Int J Pharm 194(1); 81-89.
Kim, M. K„ G. J, Choi, et al. (2003). "Fungicidal property of Curcuma longa L.
rhizome-derived curcumin against phytopathogenic fungi in a greenhouse." J
Aerie Food Chcm31(6): 1578-1581.
Kim, T. H., H. H. Jiang, et ai. (2010). "Preparation and characterization of water-
soluble albumin-bound curcumin nanoparticle.s with improved antitumor
activity." Int J Pharm.
......T85'~.....
D evelopinenl o f N ovel F orm ula tionx.... R eferen ces
K,imura, M., M. Shizuki, et al. (1994). "Relationship between the molecular structures
and emulsification properties of edible oils.” .Btosci. Biotech. Biochem. 58;
1258-1261.
Kocbek, P., S. Baumgartner, et al. (2006). "Preparation and evahiation of
rianosuspensions for enhancing the dissolution of poorly soluble drugs,"
IntenuUionai Journa! of Pharmaceutics 3 1,2( 1 -2): 179-186.
Kohli, K,, S. Chopra, et al. (2010). "Self--eniulsifying drug delivery systems: an
approach to enhance oral bioavailabiiity.” Drug Discov Today.
Komrnuru, T. B. Gurley, et al. (2001). "Sclf-emulsifying drug delivery systems
(SEDDS) of coenzyme QIO; formulation development and bioavailabiiity
assessment." Int J Pharm 212(2): 233-246.
Konwarh, R., .f. P. Saikia, et al (2010). "'Poly(ethylene glycol)-magnetic nanoparticles-
curcumin' trio: directed morphogenesis and synergistic free-radical scavenging."
Colloids Surf B Biointerfaces 81.(2): 578-586.
Kumar, M. N. V, R., U. Bakowsky, et al. (2004). "Preparation and characterization of
cationic PLGA nanospheres as DNA carriers." Bioroateriais 25(10): 1771-1777.
Kuinar, V. V„ I), Chaudrasekar, et al. "Development and evaluation of nitrendipine
loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on
plasma pharmacokinetics." International Journal of Pharmaceutics In Press,
Corrected Proof.
Kunnumakkara, A. B., P. Diagaradjane, et al. (2009). "Curcumin sensitizes human
colorectal cancer to capecitabine by modulation of cyclin Dl, COX-2, MMP-9,
VEGF and CXCR4 expression in an orthotopic mouse model." Int J Cancer
125(9): 2187-2197.
Lao, C. D., M. T, t. Ruffin, et a l (2006). "Dose escalation of a curcuminoid
formulation." BMC Complement Altern Med 6: 10.
Li, H., Y. Che, et a l (2002). "[Effects of curcumin on proliferation and apoptosis in
human hepatic cells]." Zhonghua Gan Zang Bing Za Zhi 10(6): 449-451.
Li, L., B. Ahnied, et al. (2007). "Liposomal curcumin with and without oxaliplatin:
effects on cell growth, apoptosis, and angiogenesis in colorectal cancer." Mol
Cancer Ther 6(4): 1276-1282.
Li, L., F. S. Braiteh, et al. (2005), "Liposome-encapsulated curcumin: in vitro and in
vivo effects on proliferation, apoptosis, signaling, and angiogenesis." Cancer
104(6): 1322-1,331.
.... ................ '
Devt'lopmetU o f Novel Formulations....References
iiixi, Cl P., I". Chu, et ai. (2001). "Tlie curry spice curcumin reduces oxidative damage
and amyloid pathology in an Alzheimer transgenic mouse." i Neurosci 21(21):
8370-8377.
Lioritas, A. and H. Yegcr (2004). "Curciiiriin and resveratrol induce apoptosis and
nuclear translocation and activation of p53 in human neuroblastoma."
Anticancer Res 24(2B): 987-998.
Liu, L„, R, Wang, et al. (2010). "Cloning and soluble expression of mature {alpha}-
luffin from Luffa cylindrica and its antitumor activities in vitro." Acta Biochim
Biophvs Sin (Shanghai) 42(8): 585-592.
lJu, Z. J,, G. Han, et al. (2009). "[Preparation and drug releasing property of curcumin
nanoparticles]." Zhong Yao Cai 32(2); 277-279.
Liversidge, G. G. and P, Conzentino (1995), "Drug particle size reduction for
decreasing gastric irritancy and enhancing absorption of naproxen in rats." Int.
J. Pharm. 125(2): 309-313.
Lii, P., Q. Tong, et ai. (2005). "Preparation of curcumin prodrugs and their in vitro anti-
tumor activitie,s." J Huazhong Univ Sci Technolog Med Sci 25(6): 668-670,
678.
Luo, ¥., D. Chen, et al. (2006). "Solid lipid nanoparticles for enhancing vinpocetine's
oral bioavailability." .lournal of Controlled Release 114(1); 53-59.
Mae, S. H,, M. Sofia, et al. (2008). "Selectivity of compounds isolated from the leaves
of Nerium indicum Mill, on various human cancer cell lines." Med J Malaysia
63 Suppl A: 24-25.
Mahady, G. B., S. L. Pendland, et al. (2002). "Turmeric (Curcuma longa) and curcumin
l/ihibit the growth of Helicobacter pylori, a group 1 carcinogen." Anticancer Res
22(6C): 4179-4181.
Maincent, P., R. L. Verge, et ai. (1986). "Disposition kinetics and oral bioavailability of
vincamine-loaded polyalky! cyanoacrylate nanoparticles." J. Pharm. Sci 75:
955-958.
Maiti, K., K. Mukherjee, et al. (2007). "Ctirciimin-phospholipid complex: Preparation,
therapeutic evaluation and pharmacokinetic study in rats." Int J Pharm 330(I--2):
155-163.
Marczylo, T. H., R. D. Verschoyle, et al. (2007). "Comparison of systemic availability
of curcumin with that of curcumin formulated vt'ith phosphatidylcholine."
Cancer Chemother Pharmacol 60(2): 171-177.
Developmenl o f Novel Fonmdutkms.... References
Malray-Devoti, J. (2006). Cancer Drug.s, Chelsea House Publishers.
Mazumdar, U. K., M. Gupta, et: al. (1997). "Antitumor activity of Hygrophila spinosa
on Ehrlich ascites carcinoma and sarcoma-180 induced mice." Indian .1 Exp Biol
35(5): 473-477,
Mehrotra, T. N. and G. Cardinali (1965). "Effect of Colchicine and Catharanthus
Ro.seus (Vinca Rosea) Alkaloids on Mitosis of Syrian Hamster Bone Marrow
Celis." Indian J Pathol Bacteriol 39: 98-102.
Meinzer, A., E. Muelier, et al (1995). "Microemulsions a suitable galenical approach
for the ab.sorption enhancement of low soluble drugs." B.T. Gattefosse 88: 21-
26.
Meliado, W., N. F. Magri, et ai. (1984). "Preparation and biological activity of taxol
acetates." Biochem Biophvs Res Commun 124(2): 329-336.
Merisko-Liversidge, E., G. G. Liversidge, et al. (2003). "Nanosiziiig: a formulation
approach for poorly-water-soluble compounds." Eur. .f. Pharmac. Sci. 18(2):
113420.
Moghaddaiii, S. J., P. Barta, et al. (2009). "Curcumin inhibits COPD-fike airway
inflammation and lung cancer progression in mice," Carcinogenesis 30(11):
1949-1956.
Molpeceres, J., M. Guzman, et al. (1996). "Application of central composite designs to
the preparation of polycaprolactone nanoparticie.s by solvent displacement." I
Pharm. Sci. 85(2): 206-213.
Mukhopadhyay, A., C. Bueso-Ramos, et al. (2001). "Curcumin downregulates cell
survival mechanisms in human prostate cancer cell lines." Oncogene 20(52):
7597-7609.
Mulik, R., K. Mahadik, et al. (2009). "Development of curcuminoids loaded poly(butyl)
cyanoacrylate nanoparticles; Physicochemical characterization and stability
study." Eur J Pharm Sci 37(3-4): 395-404.
Mulik, R. S., J. Monkkonen, et al. (2010). "Transferrin mediated solid lipid
nanoparticles containing curcumin; Enhanced in vitro anticancer activity by
induction of apoptosis." Int J Pharm 398(1-2): 190-203.
Naidu, K. A. and N. B. Thippeswamy (2002). "Inhibition of human low/ density
lipoprotein oxidation by active principles from .spices." Mol Cell Biochem
229(1-2); 19-23.
188
D eveloiimerit o f N ovel F orm ula tions....K eference.s
Nakagavva-Goto, K., K. Yamada, et al. (2007). "Antitumor agents. 258. Syntheses and
evaluation of dietary antioxidant-taxoid conjugates as novel cytotoxic agents."
Bioorg Med Chem Lett 17(18): 5204-5209.
National Insdtute of Medical Statistics (NIMS), I. (2010). "The Clinical Trials
Registry- India (CTRI)." 2010, ft'om http://l64.100.72.67/ClinicaitriaIs/.
National Institutes of Health (NIH), IJ. F. (2010). "Home - Clinicarrrials.gov." 2010,
frorn http ://c! i n ical tri als. gov/.
Navis, I , P. Sriganth, et al, (1999). "Dietary curcumin with cisplatin administration
modulates tumour marker indice.s in experimental fibrosarcoma." Pharmacol
Res 39(3): 175-179.
Nazzal, S., Smalyukh, II, et al (2002). "Preparation and in vitro characterization of a
eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS)
of ubiquinone: mechanism and progress of emulsion formation." Int J Pharm
235(1-2): 247-265.
Notarbartolo, M., P. Poma, et al. (2005). "Antitumor effects of curcumin, alone or in
combination w/ith cisplatin or doxorubicin, on human hepatic cancer ceils.
AnalyfJi.s of their po.ssible relationship to changes in NF-kB activation levels and
in lAP gene expression." Cancer Lett 224(1): 53-65.
O'Driscoll, C. M. (2002). "Lipid-based formulations for intestinal lymphatic delivery."
European journal of pharmaceutical sciences 15(5): 405-415.
O'Driscoll, C. M. and B. T. Griffin (2008). "Biopharmaceutical challenges associated
w'ith dnigs with low aqueous solubility-the potential impact of lipid-based
formulations." Adv Drug Deliv Rev 60(6): 617-624.
O'Sullivan-Coyne, G., G. C. O'Sullivan, et al. (2009). "Curcumin induces apoptosis-
independent death irt oesophageal cancer cells." Br J Cancer 101(9): 1585-1595.
O’Hara, T., Adrian Dunne, et al. (1998). "A review of methods used to compare
dissolution profile data." Pharmaceutical Science and Technology Today 5:
214-223.
Obitte, N. and A. Chukwu (2010). "The excipient usefulness of carbosil® and
Landolphia owariensis in two oil-based self-emulsifying formulations." Asian
Journal of Pharmaceutics 4(4): 213.
Odeberg, J. M., P. Kaufmann, et a l (2003). "Lipid drug delivery and rational
formulation design for lipophilic drugs with low oral bioavailability, applied to
cyelosporine." Eur J Pharm Sci 20(4-5): 375-382.
.....
D evelopm i'n t o f N o vel F o rm u la tio n s ....R e feren ces
Ohashi, Y., Y, Tsuchiya, et al. (2003). "Prevention of intrahepatic metastasis by
curcuniin in an ortiiotopic inipiantatiori model." Oncology 65(3): 250-258.
Onoue, S., H, Takahashi, et al. (2010). "Formulation design and photochemical studies
on nanocrystal solid dispersion of ciircmnin with improved oral bioavailability.''
J Pharm Sci 99(4): I87M881.
Padmaja, S. and T. N. Raju (2004). "Antioxidant effect of curciimin in selenium
induced cataract of Wistarrats." Indian J Esp Biol 42(6): 601-603.
Palamakiila, A. and M. A. Khan (2004). "Evaluation of cytotoxicity of oils used in
coenzyme (JIO Seli^emulsifying Drug Delivery Systems (SEDDS)." Int J Pharm
273(1-2): 63-73.
Pan, M. H., T. M. Hiuuig, et al. (1999). "Biotransformation of curciimin through
reduction and glucuronidation in mice." Drug Metab Dispos 27(4): 486-494.
Parsdya, U., M. K. Saini, et al. (2000). "Dietary curcumin prevents ocular toxicity of
naphthalene in rats." Toxicol Ixtt 115(3): 195-204.
Paradkar, A., A. A. Ambike, et al. (2004). "Characterization of curcumin-PVP solid
dispersion obtained by spray drying." International .fournal of Pharmaceutics
271(1-2): 281-286.
Paradkar, A„ A. A. Ambike, et al. (2004). "Chai'acterization of curcumin-PVP solid
dispersion obtained by spray drying." Int J Pharm 271(1-2): 281-286.
Parimala, R. and P. Sachdanandam (1993). "Effect of Plumbagin on some glucose
metabolising enzymes studied in rats in experimental hepatoma." Mol Cell
Biochem 125(1): 59-63.
Park, C., G, Y. Kim, et al. (2006). "Induction of G2/M arrest and inhibition of
cycIooxygenase-2 activity by curcumin in human bladder cancer T24 cells."
Oncol Rep 15(5): 1225-1231.
Patel, D. and K. K. Sawant (2009). "Self micro-emulsifying drug delivery system;
formulation development and biopharmaceutical evaluation of lipophilic drugs."
CuiT Drug Deliv 6(4): 419-424.
Patel, V. B„ S. Misra, et al. (2010). "Colorectal cancer: chemopreventive role of
curcumin and resveratrol." Nutr Cancer 62(7): 958-967.
Perkins, S., R. D. Verschoyle, et al. (2002). "Chemopreventive efficacy and
pharmacokinetics of curcumin in the min/+ mouse, a model of familial
adenomatous polyposis." Cancer Epidemiol Biomarkers Prev 11(6): 535-540.
190
D evclapm eni o f N avel F o m n ik itio n s ...R eferences
I’oliisa, K., A, N. Naiciu, et al. (2004). "Inhibition of B(a)P iiKluced strand breaks in
presence of cufcumin." Mutat Res 557(2): 203-213.
Poma, P., M. Notarbartolo, et al. (2007). ’’T!ie antitumor activities of curcumin and of
its isoxazole analogue are not affected by multiple gene expression changes in
an MDR model of the MCF-7 breast cancer cell line; analysis of the possible
molecular basis." Int J Mol Med 20(3): 329-335.
Ponchel, G., M, Montisd, et al. (1997). "Mucoadhesioii of colloidal particulate systems
in the gastro-intestinal tract." Ear. J. Pharrn. Biopharm. 44(1): 25-31.
Pouton, C. W. (2(K)0). "Lipid formulations for oral administration of drugs: non-
emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery
systems." Bur J Pharm Set 11 vSuppl 2: S93-98.
Ponton, C. W. (2006). "Formulation of poorly water-soluble drugs for oral
administration: physicochemical and physiological issues and the lipid
formulation classification system." Eur J Pharm Sci 29(3-4): 278-287.
Pouton, C. W. and C. J. Porter (2008), "Formulation of lipid-based delivery systems for
oral adrninistradon: materials, methods and strategies." Adv Drug Pcliv Rev
60(6); 625-637.
Pouton, C. W., M. G. Wakerly, et al. (1987). Self-emulsifying systems for oral delivery
of drugs. Int. Symp, Control Release Bioactive Materials.
Prashar, R., A. Kumar, et al. (1994). "Chernopreventive action by an extract from
Ocimum sanctum on mouse skin papillomagenesis and its enhancement of skin
glutathione S-transferase activity and acid soluble sulfydryl level." Anticancer
a ilfis , 5(5): 567-572.
Punithavathi, D., N. Venkatesan, et al (2003). "Protective effects of curcumin against
itmiodarone-induced pulmonary fibrosis in rats." Br J Pharmacol 139(7); 1342-
1350.
Quiles, J. L,, M. D. Mesa, et al. (2002). "Curcuma longa extract supplementation
reduces oxidative stress and attenuates aortic fatty streak development in
rabbits." Arterioscler Thromb Vase Biol 22(7): 1225-1231.
Quiroga, A,, P. L. Quiroga, et a l (2010). "Anti-breast cancer activity of curcumin on
the human oxidation-re,sistant cells ZR-75-1 with gamma-
glutamvltranspeptidase inhibition." J Exp Ther Oncol 8(3): 261-266.
Radhakrishna Pillai, G., A. S. Srivastava, et a l (2004). "Induction of apoptosis in
human lung cancer cells by curcumin." Cancer Lett 208(2): 163-170.
.................. ...
Development o jN ovel Foruudcitionx....References
Rafiee, P., H. Ogawa, et ai. (2003). "Isolation and characterization of human
esopiiageal inicrovascular endothelial cells: mechanisms of inflammatory
activation." Am J Physiol Gastrointest Liver Phvsiot 285(6); GI277-1292.
Ramachanclran, C., A. P. Resek, et al. (2010). "Potentiation of gemcitabine by Turmeric
Force in pancreatic cancer cell line.s." Oncol Rep 23(6): 1529-1535.
Rashmi, R., T. R. Santhosh Kumar, et al. (2003). "Human colon cancer cells differ in
their sensitivity to curcumin-induced apoptosi.s and heat .shock protect.s them by
inhibiting the release of apoptosi.s-inducing factor and caspaaes." FEBS Lett
.538(1-3): 19-24.
Ravindranath, V. and N. Chandrasekhara (1980). "Ab.sorption and tissue distribution of
curcumin in rats." Toxicology 16(3): 259-265.
Ravindranath, V. and N. Chandrasekhara (1981). "Metabolism of curcumin-studies
with [3H]curcumin." Toxicology 22(4); 337-344.
Reddy, V. V. and M. Sirsi (1969). "Effect of Abrus precatorius L. on experimental
tumors.” Cancer Res 29(7): 1447-1451.
Reiss, H. (1975). "Entropy induced di.spersion of bulk liquids." .T Colloid Interface Sci
53(1); 61-70.
Ritschel, W. and G. Kearns (1999). Handbook of basic pharmacokinetics- including
clinical application.s. American Pharmaceutical Association.
Rooney, S. and M. F. Ryan (2005). "Effects of alpha-hederin and thymoquinoiie,
constituents of Nigella sativa, on human cancer cell lines," Anticancer Res
25(3B): 2199-2204.
Roy, M., S. Chakraborty, et al. (2002). "Induction of Apoptosis in Tumor Cells by
Natural PhcnoHc Compounds." Asian Pac J Cancer Prev 3(!): 61-67.
Rukkumani, R., M. Sri Balasubashini, et al. (2002). "Comparative effects of curcntain
and photo-irradiated curcumin on alcohol- and polyunsaturated fatty acid-
induced hyperlipidemia." Pharmacol Res 46(3): 257-264.
Russell-Jones, G. L. Arthur, et al. (1999). "Vitamin B12-mediated transport of
nanoparticles across Caco-2 ceils." Int. J. Pharm. 179(2): 247-255.
Sakurna, S., N. Suzuki, et al. (1997). "Oral peptide delivery using nanoparticles
composed of novel graft copolymers having hydrophobic backbone and
hydrophilic branches." Int. J. Pharm. 149(1): 93-106.
Sanchez, Y„ G. P. Simon, et al. (2010). "Curcumin stimulates reactive oxygen species
production and potentiates apoptosis induction by the antitumor drugs ai'senic
192“""..
Development o f Novel Formulations....References
trioxidc and lonidamine in iiunian myeloid leukemia ceil lines." J Phannacol
Exp Ther 335(1): 114.123.
Savidge, T. C, M. W. Smith, et al, (1991). "Salmonella-induced M-cell formation in
gerai-free mouse Peyer'.s patch tissue." Am. J. Path 139; 177-184,
Setthaciieewakul, S., S. Mahattanadul, et al. (2010). "Development and evaluation of
self-microemulsifying liquid and pellet formulations of curcuinin, and
absorption studies in rats." Eur J Pharm Biooharm.
Shafiq, S., F. Sliakeel, et al. (2007). "Development and bioavailability assessment of
ramipril nanoeniulsion formulation." Eur J Pharm Biooharm 66(2); 227-243.
Shah, N. H., M. T. Carvajal, et al. (1994). "Self emulsifying drug delivery systems
(SEDDS) with poiyglycolyzed glycerides for improving in vitro dissolution and
oral absorption of lipophillic drugs." International Journal of Pharmaceutics
106(1); 15-23.
Shaikh, L, D. D. Ankoia, et al (2009). "Nanoparticfe encapsuiation improves oral
bioavailability of curcumin by at least 9-foid when compared to curcumin
administered with piperine as absorption enhancer." Eur J Pharm Sci 37(3-4):
223^230.
Shao, Z. M., Z. Z. Shen, et al. (2002). "Curcumin exertis multiple suppressive effects on
human breast carcinoma cells." Int J Cancer 98(2): 234-240.
Sharma, R. A,, S. A. Euden, et al. (2004). "Phase I clinical trial of oral curcumin:
biomarkers of systemic activity and compliance." Clin Cancer Res 10(20):
6847-6854.
Sharma, R. A., C. R. Ireson, et til. (2001). "Effects of dietary curcumin on glutathione
S-transferase and malondialdehyde-DNA adducts in rat liver and colon mucosa:
relationship with drug levels." Clin Cancer Res 7(5): 1452-1458.
Sharma, R. A., W. P. Steward, et al. (2007). "Pharmacokinetics and pharmacodynamics
of curcumin." Adv E x p Med Biol 595: 453-470.
Shicheng, Y., G. R. Neslihan, et al (2004). "Enhanced oral absorption of Paclitaxel in a
novel self microemulsifing drug delivery sysytem with or without concomittant
use of P-Glycoprotein inhibitors." Pharm Res 21(2): 261-270.
Shishodia, S., P. Potdar, et al. (2003). "Curcumin (difeniloylmethane) down-regulates
cigarette smoke-induced NF-kappaB activation through inhibition of
IkappaBalpha kinase in human lung epithelial cells: correlation with
193
Development v f Novel Fommlalions....References
.suppression of COX-2, MMP-9 and cyclin Dl." Carcinogenesis 24(7); 1269-
1279.
Shoba, (3., D. Joy, et al. (1998). "Influence of pipeline on the pharmacokinetics of
curcurairi in animals and human volunteers." Planta Med 64(4): 353-356.
Silva, B. F., E. F. Marques, et al. (2(H)9). "Size, shape, and charge of sait-free
catanionic microemulsion droplets: a .sraall-angle neutron scattering and
modeling study." J Phvs Chem B 113(30): 10230-10239.
Singh, B., S. Bandopadhyay, et al. (2009). "Self-emulsifying drug delivery systems
(SEDDS): formulation development, characterization, and applications." Crit
Rev Ther Drug Carrier Svst 26(5); 427-521.
Singh, M. and N. Singh (2010). "Curcumin counteracts the proliferative effect of
estradiol and induces apoptosis in cervical cancer cells." Mol Cell Biochem.
Singh, S. and M. Bakshi (2000). "Guidance on conduct of stress tests to determine
inherent stability of drugs." Pharmaceutical Technology Online(April): 1-14.
Sinha* R., D. E. Anderson, et al. (2003). "Cancer risk and diet in India." J Postgrad Med
49(3): 222-228.
Skommer, J., D. Wlodkowic, et al. (2006). "Cellular foundation of curcumin-induced
apoptosis in follicular lymphoma cell lines." Exp Hematol 34(4); 463-474.
Song, C. X., V. Labhasetwar, et al. (1997). "Formulation and characterization of
biodegradable nanoparticles for intravascular local drug delivery." J. Control.
Release 43(2-3): 197-212.
Sou, K., S, Inenaga, et al. (2008). "Loading of curcumin into macrophages using lipid-
based nanoparticles." Int J Pharm 352(1-2): 287-293.
Sou, K., B. Oyajobi, et al. (2009). "Characterization and cytotoxicity of self-organized
’ assemblies of curcumin and amphiphatic poly(ethylefie glycol)." J Biomed
Nanotechnol 5(2): 202-208,
Sreejayan and M. N. Rao (1997). "Nitric oxide scavenging by curcuminoids." J Pharm
Pharmacol 49(1): 105-107.
Srinivasan, P. and B. Libbus (2004). "Mining MEDLINE for implicit links between
dietary substances and diseases." Bioinformatics 20 Suppl 1:1290-296.
Stankovic, I. (2004). "Curcumin ~ Chemical and Technical Assessment (CTA)." 61st
JECPA 2004. 2010, from
ftp://ftD.fao.org/es/esn/iecfa/cta/CTA 61 Curcumin.pdf.
194
Development o f Novel P'orinidations,...References
,Su, C. C., J. S. Yang, ec al. (2,010). "Curcumin inhibits human lung large cell carcinoma
cancer tumour growth in a murine xenograft model." Phvtother Res 24(2): 189-
192,
Subramanian, N,, S. Ray, et al. (2004). "Formulation design of seif-microemulsifying
drug delivery systems for improved oral bioavailabiiity of ceiecoxib." Biol
Pharm Bull 27(12); 1993-1999.
Suryanarayana, P., K. Krishnaswamy, et al. (2003). "Effect of curcumin on galactose-
induced cataractogenesis in rats." Mol Vis 9: 223-230.
Swenson, E. S., W. B. Milisen, et al. (1994). "Intestinal permeability enhancement;
efficacy, acute local toxicity and reversibility." Pharm Res 11(8); 1132-1142.
Syu, W. J., C. C. Shen, et al. (1998). "Cytotoxicity of curcuminoids and some novel
compounds from Curcuma zedoaria." J Nat Prod 61(12): 1531-1534.
Takeuchi, H., H. Yamamoto, et ai. (2001). "Mucoadhe.sive nanoparticulate systems for
peptide diiig delivery." Adv. Drug Del. Rev. 47(1): 39-S4.
Tammariello, A. E, and J. A. Milner (2010). "Mouse models for unraveling the
importance of diet in colon cancer prevention." J Nutr Biochcm 21(2); 77-88.
Teiten, M. H., F. Gaascht, et al. (2010). "Chemopreventive potential of curcumin in
prostate cancer," Genes Nutr 5(1): 61-74.
Tharakan, S. T., T. Inamoto, et a l (2010). "Curcumin potentiates the antitumor effects
of gemcitabine in an orthotopic model of human bladder cancer through
suppression of proliferative and angiogenic biomarkers." Biochem Pharmacol
79(2): 218-228.
Thompson, K. H., K. Bohmerie, et al. (2004). "Complementary inhibition of
synoviocyte, smooth muscle cell or mouse lymphoma cell proliferation by a
vanadyl curcumifl complex compared to curcumin alone." J Inorg BioChem
98(12); 2063-2070.
Tiyaboonchai, W., W. Tungpradit, et al. (2007). "Formulation and characterization of
curcuminoids loaded solid lipid nanopaiticles." Int J Pharm 337(1-2); 299-306.
Tobio, M., A. Sanchez, et al (2000). "The role of PEG on the stability in digestive
fluids and in vivo fate of FEG-PLA nanoparticles following oral
administration." Colloids ans Surfaces B: Biointerfaces 18: 315-323.
Tomida M., H. Ohtake, et al. (2008). "Stat3 up-regulates expression of nicotinamide
N-methyltransferase in human cancer cells." J Cancer Res Clin Oncol 134(5):
551-559.
Development o f N o vel Formulations.. ..References
Tonnesen, H. H. and J. Karlsen (1985). "Studies on curcumin and curcuminoids. V
■Alkaline degradation of curcumin." Z Lebensrn Unters Forsch 180(5): 132-134.
ToiineserL, H. H. and J. Karlsen (1985). "Studies on curcumin and curcuminoids. VL
Kinetics of curcumin degradation in aqueous solution." Z Leben.sm Unters
Forsch 180(5): 402-404.
Tunstall, R. G., R. A. Sliarma, et ai. (2006). "CyclooxygenawSe-2 expression and
oxidative DNA adducts in murine intestinal adenomas; modification by dietary
curcumin and implications for clinical trials." Eur J Cancer 42(3): 415-421.
Ukii, A., S. Maity, et al. (2003). "Curcumin, the major component of food flavour
turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced
colitis." BrJ Pharmacol 139(2): 209-218.
USFDA. (1997, September, 1997). "Guidance Ibr Industry SUPAC-MR: Modified
Release Solid Oral Dosage Forms." Retrieved Feb. 20, 2004, from
h«:p://wwvi^.fda.gov/cdcr/guidancc/index.hl:m.
USFDA (2001). Guidance For Industry - Bioanalytical Method Validation. F. a. D. A.
U.S. Department of Health and Human Services, Center for Drug Evaluation
and Research, Center for Veterinary Medicine. Rockville, MD.
van't Land, B., N. M. Blijievens, et al. (2004). "Role of curcumin and the inhibition of
NF-kappaB in the onset of chemotherapy-induced mucosal barrier injury."
Leukemia 18(2); 276-284.
Vandervoort, J. and A. Ludwig (2002). "Biocompatible stabilizers in the preparation of
PLGA nanoparticles: a factorial design study," Int. J. Pharm. 238(1-2): 77-92.
Venkatesh, G., M. L Majid, et al "In vitro and in vivo evaluation of self-
microemulsifying drug delivery system of buparvaquone." Drug Dev Ind
Pharm.
Vonderscher, J, and A. Meinzer (1994). Rationale for the development of Sandimmune
Neoral. Transplantation proceedings.
Vyas, S. P. and R. K. Khar (2002). Submicron Emulsion. Targeted and controlled drug
delivery novel caitiers systems. New Delhi, CBS publishers and distributors:
291-294.
Wahlang, B., Y. B. Pawar, et al. (2010). "Identification of permeability-related hurdles
in oral delivery of curcumin using the Caco-2 cell model." European Journal of
Pharmaceutics and Biopharmaceutics.
196
Development o f Novel Farnudatkms....References
Wiihlstrorn, B. and G. Bletmow (1978). "A study on the fate of curcurnin in the rat."
Acta Pharmacol Toxicol ('Coperih) 43(2); 86-92.
Wang, W., FI Zhatig, et al. (2010). "[Anticancer activities of curcumin on human
hepatocarcinoma ceil line Slc-hep-1]," Zhongguo Zhong Yao Za Zhi 35(4): 485-
488.
Wang, y. J., M. H. Pan, et al. (1997). "Steibility of curcumin in buffer solutions and
characterization of its degradation products." j Pharm Biomed Anal 15(12):
1867-1876.
Wargovich, M. .1., C. D. Chen, et al. (1996). "Aberrant crypts a.s a biomarker Ibr colon
cancer: evaluation of potential chemopreventive agents in the rat." Cancer
Epidemiol Bioinarkers Prev 5(5): 355-360.
Wax, A., J. W. Pyhtila, et al (2005). "Prospective grading of neoplastic change in rat
e.sophagus epithelium using angle-resolved iow-coherence interferometry." J
Biomed Opt 10(5); 051604.
Wei, L., P. Sue, et al. (2005), "Preparation and evaluation of SEDDS and SMEDDS
containing carvedilol." Drug Dev Ind Pharm 31(8): 785-794.
Wei, S. C., Y, S. Lin, et al. (2004). "Comparison of the anti-proliferation and apoptosis-
induction activities of sulindac, celecoxib, curcumin, and nifedipine in
mismatch repair-deficient cell lines." J Formos Med Assoc 103(8): 599-606.
Werkley, M. G., C. W. Poutoii, et al. (1986). "Self einulsifiaction of vegetable oil-non~
ionic surfactant mixtures," ACS Svmp. Series 311: 242-255.
White, E. L., L. J. Ross, et al. (1998). "Screening of potential cancer preventing
chemicals for induction of glutathione in rat liver cells." Oncol Rep 5(2): 507-
512.
WHO. (2009). "Cancer, Fact sheet N“297." Retrieved'09.11.2010, 2010, from
http://vyww.who.int/mediacentre/faclsheets/fs297/en/print.html.
WHO. (2010). "Welcome to the WHO ICTRP." 2010, from
http://www.who.int/ictrp/en/.
Wiener, C., E. Braunwald, et al, (2004). Harrison's principles of internal medicine: self-
assessment and board review. McGraw-Hill, Medical Pub, Division.
Wijnands, M, V., M, J. van Erk, et al. (2004). "Do aberrant crypt foci have predictive
value for the occurrence of colorectal tumours? Potential of gene expression
profiling in tumours." Food Chem Toxicol 42(10): 1629-1639.
197
D evelopm ent ojN ovel Fonnulations,...References
Wu, W., J. Shen, et al. (2010). "Water-dispersible multifunctional hybrid nanogels for
combined curcumin and photothermal therapy," BioiTiateriais.
Wu, X., J. Xu, et af. (2010). ''Self-microernulsifying drug delivery system improves
curcumin dissolution and bioavailability." Drug Dev Ind Pharm.
Wu, Y„ A. Loper, et al. (2004). "The role of biopharmaceutics in the development of a
clinical nanoparticle formulation of MK-0869; a Beagle dog model predicts
improved bioavaiiability and diminished food effect on absorption in human."
Int. J, Pharm. 285(1-2): 135-146.
Xu, D. H,, S. Wang, et al, (2008). "[StudicK on solubility enhancement of curcumin by
polyvinylpyrrolidione K30]." Zhong Yao Cai 31(3); 438-442.
Yallapu, M. M., B. K. Gupta, et al. (2010). "Fabrication of curcumin encapsulated
PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells."
J Colloid Interface Sci 351(1): 19-29-
Yaliapu, M. M., D. M. Maher, et al. (2010). "Curcumin induces chemo/radio-
sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian
cancer cell grovi/th." J Ovarian Re.s 3: 11.
Yang, K. Y., L. C. Lin, et al. (2007). "Oral bioavaiiability of curcumin in rat and the
herbal analysis from Curcuma longa by LC-MS/MS." J Chromatogr B Analvt
Technol Biomed Life Sci 853(1-2): 183-189.
Yen, F. L., T. H. Wu, et al. (2010). "Curcumin nanoparticles improve the
physicochemical properties of curcumin and effectively enhance its antioxidant
and antihepatoma activities." J Aerie Food Chem 58(12): 7376-7382.
Yu, Y., S. S. Kanwar, et al (2009). "Elimination of Colon Cancer Stem-Like Cells by
the Combination of Curcumin and FOLFOX." Transl Oncol 2(4): 321-328.
Zhang, C., B. Li, et al. (2010). "Curcumin selectively induces apoptosis in cutanetius T-
cell lymphoma cell lines and patients' PBMCs: potential role for STAT-3 and
NF-kappaB signaling." J Invest Dermatol 130(8): 2110-2119.
Zhao, B. L., X. J. Li, et al. (1989). "Scavenging effect of extracts of green tea and
natural antioxidants on active oxygen radicals." Cell Biophvs 14(2): 175-185.
Zheng, M., S. Ekmekcioglu, et al. (2004). "Inhibition of nuclear factor-kappaB and
nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human
melanoma cells." Melanoma Res 14(3): 165-171.
Zheng, Z., X. Zhang, et al. (2010). "Sonication-assisted synthesis of polyelectrolyte-
coated curcumin nanoparticles." Langmuir 26(11): 7679-7681..... ---====1== ^
D t’vtdopitH'iil o f N o vel I'orimilcilioiis. ..Reference.s
Ihu., X. M. Siiii, et al. (2010). "|Prepar;jtion and characterization of curcumin
polybutylcyanoacrylate nanoparticles].'' ZhoriK Yao Cai 33(5): 797-80!.
199